Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers

This article is protected by copyright. All rights reserved.

Source: Diabetes, Obesity and Metabolism - November 9, 2018 Category: Endocrinology Authors: Hiddo J.L. Heerspink, C. David Sj öström, Silvio E. Inzucchi, Melissa K. Hallow, Valerie A. Cain, Peter Rossing, Bergur V. Stefansson, Peter Sartipy Tags: BRIEF REPORT Source Type: research